← Search & browse all drugs

sotagliflozin

A10BK06

Forms & Strengths

Oral tablets: 200 mg
Oral tablets: 395 mg

Adult Dosing

Heart failure, type 2 diabetes mellitus, chronic kidney disease: 200 mg orally once daily before the first meal of the day
May be increased to 395 mg orally once daily based on tolerability and clinical response
Renal impairment: Not recommended if eGFR < 25 mL/min/1.73m2

Pediatric Dosing

Safety and efficacy in pediatric patients (< 18 years) have not been established

Indications

Reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors

Mechanism of Action

Dual inhibitor of sodium-glucose cotransporter 2 (SGLT2) and sodium-glucose cotransporter 1 (SGLT1)
Inhibition of SGLT2 in the proximal renal tubule reduces renal glucose and sodium reabsorption, increasing urinary glucose excretion and osmotic diuresis
Inhibition of SGLT1 in the intestinal tract delays and decreases glucose and galactose absorption

Contraindications

History of serious hypersensitivity reaction to sotagliflozin
Patients on dialysis

Adverse Reactions

Volume depletion and hypotension
Urinary tract infections
Genital mycotic infections
Diarrhea
Diabetic ketoacidosis in patients with type 1 or type 2 diabetes
Hypoglycemia (when used with insulin or insulin secretagogues)
Increased LDL cholesterol

Drug Interactions

Diuretics: May additive hypotension and volume depletion
Insulin and insulin secretagogues: Increased risk of hypoglycemia
Lithium: SGLT2 inhibitors may increase renal lithium clearance, decreasing serum lithium concentration
Digoxin: Monitor concentrations closely as tubular secretion may be affected

Curated Content: Needs Vetting Before Put to Clinical Use